The Effect of SGLT2 inhibitors on blood glucose variability in patients with type 1 diabetes

The Effect of SGLT2 inhibitors on blood glucose variability in patients with type 1 diabetes - SGLT2i and glucose variability in T1DM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039361

Enrollment

Registered

2020-02-02

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with type 1 diabetes who are treated in Hokkaido University Hospital or collaborate hospitals from December 2018 to June 2020. 2) Patients with type 1 diabetes who have been treated with SGLT2 inhibitors for more than 12 weeks.

Exclusion criteria

Exclusion criteria: Patients who were thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Change in day-to-day and daily blood glucose variability	—

Secondary

Measure	Time frame
1 Blood and urine test (HbA1c, UACR, etc) 2 Body weight, Body mass index 3 Blood pressure 4 insulin dose 5 Adverse events	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Faculty of Medicine and Graduate School of Medicine Division of Diabetes and Obesity

hmiyoshi@med.hokudai.ac.jp011-706-8192

Outcome results